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1. Introduction
The application of peptides in the pharmaceuticals and medicinal field is thrivingly emerging 
nowadays. Over the past few years, the development of peptides such as the major com-
pounds in medicines and biotechnology research has been widely utilized due to its high 
selectivity, good efficiency, predictable metabolism, and affordable prices, compared to other 
classes of drugs such as small compounds or natural products [1]. Nevertheless, the extensive 
bioactivities that peptide class possessed are promising and interestingly worthy to be inves-
tigated and developed further in the future.
Peptides are biopolymers which composed of amino acids as the monomers that connected 
through peptide bonds. The length of amino acids is varying from 2 (commonly known 
as dipeptide) to 50 amino acids (known as a polypeptide). The composition and order of 
amino acid sequences determine their properties, both physical and chemical, and also their 
pharmacological activities [2]. Regarding the structure, peptides can be classified into two 
categories: linear peptide and cyclic peptide. The linear peptide is prone to be hydrolyzed by 
exopeptidases and endopeptidases. Thus, lowering its effective half-life in the human body. 
The peptide cyclization is a familiar technique to increase the peptide stability and effective 
half-life. However, this treatment is also modifying the peptide bioactivity, either by lowering 
or raising its activity due to fixed flexibility and conformation, which have to be measured 
later on by in vivo experiments [3].
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2. Peptide as therapeutics agents
The development of peptides as the therapeutic agents had arisen since the early 1980s when 
natural peptides such as insulin and adrenocorticotrophic hormone (ACTH) were isolated 
widely and became the popular therapeutics approaches at that time. Since then, several 
synthetic peptides (i.e., vasopressin and oxytocin) and natural peptides (i.e., snake venom) 
have been introduced and identified for their use in pharmaceuticals and biotechnology fields 
[4]. As for today, more than 60 peptides have been approved for their use as drugs from 
Food and Drug Admission (FDA) and widely marketed, with other 140, and 500 peptides 
are still in clinical trials and preclinical development [1]. Therapeutic peptides have various 
known pharmacological and biological activities, including an antioxidant, antimicrobial, 
anti-inflammatory, and antihypertension [5]. Currently, the antiviral activity of peptides is 
also investigated as well, such as an anti-HIV agent [6].
One of the most significant challenges on the development of peptides as the therapeutic 
agents is to increase their oral bioavailability. Due to their enormous molecular weight, high 
polarity, low intestinal permeability, and hydrolysis susceptibility (especially for linear pep-
tide), almost all therapeutic peptides are administrated through injection. Although consider-
able efforts have been made in the advancement of peptides research, so far there are only 
eight peptide drugs that have currently sold in the market which orally administrated. The 
well-known examples of this kind of peptide are linaclotide, an oligopeptide which used to 
treat irritable bowel syndrome with constipation, and cyclosporine, which widely utilized 
as an immunosuppressant (Figure 1) [7]. To date, two approaches have been established to 
improve the oral bioavailability of the respective peptides: the first strategy would be the 
optimization of peptide structure, followed by the lead peptide alteration into its derivate 
that possessed high oral bioavailability. The second strategy, which involves the development 
of the orally available peptide backbones, has not obtained the same success as the previous 
strategy, although the potency of this strategy cannot be underestimated yet [3].
Figure 1. The molecular structure of linaclotide (left) and cyclosporine (right), one of the examples of orally administrated 
peptide drugs.
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